Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
Habib Hamidi, Yasin Şenbabaoğlu, Niha Beig, Juliette Roels, C Manuel, Xiangnan Guan, Hartmut Koeppen, Zoe J. Assaf, Barzin Y. Nabet, Adrian Waddell, Kobe Yuen, Sophia L. Maund, Ethan S. Sokol, Jennifer M. Giltnane, Amber Schedlbauer, Eloisa Fuentes, James D. Cowan, Edward E. Kadel, Viraj Degaonkar, Alexander Andreev-Drakhlin, Patrick Williams, Corey Carter, Suyasha Gupta, Elizabeth Steinberg, Yohann Loriot, Joaquim Bellmunt, Petros Grivas, Jonathan E. Rosenberg, Michiel S. van der Heijden, Matthew D. Galsky, Thomas Powles, Sanjeev Mariathasan, Romain Banchereau
Topics & Concepts
BlockadeUrothelial carcinomaCancer researchCarcinomaPD-L1BiologyMedicineOncologyInternal medicineImmunotherapyCancerBladder cancerReceptorBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesEsophageal Cancer Research and Treatment